VEGF R2 Overview
Molecule Name
Vascular endothelial growth factor receptor 2
Synonyms
KDR,CD309,FLK1,VEGFR,VEGFR2
Drug Development Progress
Drugs in Clinical Trials61
Approved Drugs18
Highest Development StageApproved
Target Synonym
EC:2.7.10.1，EC 2.7.10，VEGFR2，KDR，Vascular endothelial growth factor receptor 2，Fetal liver kinase 1，Kinase insert domain receptor，Kinase Insert Domain Receptor (A Type III Receptor Tyrosine Kinase)，Protein-Tyrosine Kinase Receptor Flk-1，FLK1，Tyrosine Kinase Growth Factor Receptor，Fetal Liver Kinase-1，Soluble VEGFR2，CD309 Antigen，EC 2.7.10.1，VEGFR-2，CD309，VEGFR，FLK-1，Vascular Endothelial Growth Factor Receptor-2
Background
Kinase insert domain receptor (KDR), also known as CD309, FLK1 and VEGFR-2, is one of the subtypes of the VEGF receptor family. VEGF receptors bind vascular endothelial growth factor (VEGF). There are three main subtypes, numbered 1, 2 and 3. They each contain an extracellular region with 7 immunoglobulin-like domains, a single transmembrane helix, and an intracellular split tyrosine kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 mediates nearly all known cellular responses to VEGF. VEGFR-1 is less well defined but is thought to modulate VEGFR-2 signaling; it may also act as a decoy receptor that sequesters VEGF, a role particularly important during embryonic vasculogenesis. Additionally, VEGFR-2 can directly interact with extracellular HIV-1 Tat protein, and this interaction appears to enhance angiogenesis in Kaposi's sarcoma lesions.
VEGF R2 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Simmitinib hydrochloride | SOMCL-15-290 | Phase 3 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Breast Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Inlecitug | Phase 3 Clinical | Changchun GeneScience Pharmaceuticals Co Ltd | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| BC-001 | BC001; BC-001 | Phase 3 Clinical | Shandong Buchang Pharmaceuticals Co Ltd | Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| XY-0206 | XY-0206 | Phase 3 Clinical | Nanjing University Of Chinese Medicine | Leukemia, Myeloid, Acute; Solid tumours | Details |
| KC1036 | KC1036; KC-1036 | Phase 3 Clinical | Beijing Konruns Pharmaceutical Co Ltd | Adenocarcinoma; Digestive System Neoplasms; Esophageal Squamous Cell Carcinoma; Hematologic Neoplasms; Neoplasm Metastasis; Sarcoma, Ewing; Solid tumours; Thymus Neoplasms | Details |
| Cediranib | AZD2171; AZD-2171; NSC-732208 | Phase 3 Clinical | Astrazeneca Plc | Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Follicular; Adenocarcinoma, Mucinous; Angioimmunoblastic T-cell Lymphoma; Ascites; Astrocytoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Burkitt Lymphoma; Carcinoma; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Carcinosarcoma; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Ependymoma; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Glioma; Gliosarcoma; Head and Neck Neoplasms; Hepatic Insufficiency; Hodgkin Disease; Hormone-Resistant Prostate Neoplasms; Hypopharyngeal Neoplasms; Intraocular Lymphoma; L | Details |
| Sitravatinib | MG-516; MG-91516; MGCD-516; IND-155305; MGCD-0516 | Phase 3 Clinical | Mirati Therapeutics Inc | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Hepatic Insufficiency; Kidney Neoplasms; Liposarcoma; Lung Diseases; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Oral Squamous Cell Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Ureteral Neoplasms; Uterine Cervical Neoplasms; Uveal melanoma | Details |
| Simmitinib | SYHA-1817 | Phase 3 Clinical | CSPC Pharmaceutical Group Ltd | Biliary Tract Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Stomach Neoplasms | Details |
| Axitinib intravitreal implant (Ocular Therapeutix) | OTX-TKI | Phase 3 Clinical | Ocular Therapeutix Inc | Diabetic Retinopathy; Macular Degeneration; Wet Macular Degeneration | Details |
| Pulocimab | AK-109; AK109 | Phase 3 Clinical | Adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Intestinal Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Recombinant Anti-VEGFR2 Fully Human Monoclonal Antibody(Jingyitaixiang Technology Development) | JY-025 | Phase 2 Clinical | Beijing Eastern Biotech Co Ltd, Beijing Jingyitaixiang Technology Development Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Liver Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| MSB-0254 | MSB-0254 | Phase 2 Clinical | Suzhou Transcenta Therapeutics Co Ltd | Solid tumours | Details |
| AUR-109 | ODM-203; AUR-109 | Phase 2 Clinical | Orion Corp | Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Pulmonary Fibrosis; Solid tumours; Urinary Bladder Neoplasms | Details |
| (-)-Epigallocatechin gallate | AB-4166 | Phase 2 Clinical | Charite Universitaetsmedizin Berlin | Alzheimer Disease; Colonic Neoplasms; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Frailty; Glaucoma, Open-Angle; Huntington Disease; Hypertension; Idiopathic Pulmonary Fibrosis; Inflammation; Insulin Resistance; Leukemia; Liver Cirrhosis; Lung Diseases, Interstitial; Multiple Sclerosis, Relapsing-Remitting; Muscular Dystrophy, Duchenne; Neoplasms; Obesity; Ocular Hypertension; Papillomavirus Infections; Parkinson Disease; Peripheral Nervous System Diseases; Prostatic Neoplasms; Uterine Cervical Diseases | Details |
| Lucitanib | S-80881; AL-3810; CO-3810; E-3810; S-80881-2 | Phase 2 Clinical | Advenchen Laboratories Nanjing Ltd | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Genital Neoplasms, Female; Lung Neoplasms; Metastatic breast cancer; Nasopharyngeal Carcinoma; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Thymus Neoplasms | Details |
| VEGFR2 peptide vaccine (VAXIMM) | VXM-01 | Phase 2 Clinical | Merck Serono | Colorectal Neoplasms; Glioblastoma; Pancreatic Neoplasms | Details |
| Telatinib | EOC-315; BAY-57-9352 | Phase 2 Clinical | Bayer AG | Solid tumours; Stomach Neoplasms | Details |
| Derazantinib | ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 | Phase 2 Clinical | Arqule Inc | Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Transitional Cell; Cholangiocarcinoma; Solid tumours; Stomach Neoplasms; Urogenital Neoplasms | Details |
| OT-202 | OT 202; OT-202 | Phase 2 Clinical | Ocumension (Hong Kong) Ltd | Xerophthalmia | Details |
| OTP-01 | OTP-01 | Phase 2 Clinical | Ottimo Pharma Ltd | Neoplasms; Solid tumours | Details |
| Inhaled Nintedanib – dry powder (Avalyn Pharma) | AP02; AP 02 DP; AP-02; AP02-DP | Phase 2 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pulmonary Fibrosis; Respiratory Tract Diseases | Details |
| BR-55 | BR-55; BR55 CEUS | Phase 2 Clinical | Sonus Pharmaceuticals Ltd | Contrast agents; Diagnostic agents; Inflammation; Neoplasms; Ovarian Neoplasms | Details |
| Axitinib Implant（Aerie） | AR-14034 SR; AR-14034 | Phase 2 Clinical | Aerie Pharmaceuticals Inc | Macular Degeneration | Details |
| K-13 | Phase 2 Clinical | Shanghai Yifeng Biotechnology Co Ltd | Neoplasms; Solid tumours | Details | |
| Sorafenib Tosylate/Comekibart | MG-D-1609 | Phase 2 Clinical | Metagone Biotech Inc | Solid tumours | Details |
| Tosposertib phosphate | TU-2218; NCE401; NCE-401 | Phase 2 Clinical | TiumBio Co Ltd | Idiopathic Pulmonary Fibrosis; Solid tumours | Details |
| VEGFR-1/2 peptide vaccine (Keio University) | Phase 2 Clinical | Keio University | Brain Neoplasms; Glioma; Neurofibromatoses | Details | |
| Gersizangitide | AXT-107 | Phase 2 Clinical | AsclepiX Therapeutics Inc | Diabetic macular oedema; Macular Degeneration | Details |
| KDR2-2 | Phase 2 Clinical | Guangzhou Huiborui Biomedical Technology Co Ltd | Corneal Neovascularization; Glaucoma, Neovascular; Neovascularization, Pathologic | Details | |
| KHK-4951 | Phase 2 Clinical | Kyowa Kirin | Diabetic macular oedema; Macular Degeneration; Macular Edema; Wet Macular Degeneration | Details | |
| CEP-11981 | ESK-981; CEP-11981; SSR-106462; BOL-303213X | Phase 2 Clinical | Sanofi | Adenoma, Islet Cell; Bone metastases; Carcinoma, Adenosquamous; Carcinoma, Neuroendocrine; Gastrointestinal Neoplasms; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| Axitinib injectable suspension (Clearside Biomedical) | CLS-1002; CLS-011-A; CLS011A; CLS-AX | Phase 2 Clinical | Clearside Biomedical Inc | Macular Degeneration | Details |
| Hydroxychloroquine/Sorafenib | Phase 2 Clinical | Vg Life Sciences | Ovarian Neoplasms; Solid tumours | Details | |
| EDP317 | ACTB-1003; EOC-317; EDP-317 | Phase 1 Clinical | Act Biotech Inc, Bayer AG | Biliary Tract Neoplasms; Breast Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms | Details |
| Kanitinib | CX-1003 | Phase 1 Clinical | Beijing Konruns Pharmaceutical Co Ltd, Guangzhou Yingsheng Bio Technology Co Ltd | Solid tumours | Details |
| VEGFR2 peptide vaccine (Tokyo University) | Phase 1 Clinical | University Of Tokyo | Pancreatic Neoplasms | Details | |
| Brivanib Alaninate | ZL-2301; BMS-540215; BMS-582664 | Phase 1 Clinical | Bristol-Myers Squibb Company | Adenocarcinoma, Clear Cell; Asthma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Gastrointestinal Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Pulmonary Disease, Chronic Obstructive; Rectal Neoplasms; Sarcoma; Solid tumours; Uterine Cervical Neoplasms | Details |
| Ramucirumab biosimilar (Henlius) | HLX-12 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Stomach Neoplasms | Details | |
| Timtraxanib | AVI-3207 | Phase 1 Clinical | Avixgen | Macular Degeneration | Details |
| Pamufetinib | TAS-115 | Phase 1 Clinical | Otsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd | Neoplasms | Details |
| nintedanib (Avalyn Pharma) | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis | Details | |
| Ramucirumab biosimilar (Sichuan Kelunbotai Biopharmaceutical) | Phase 1 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| Tafetinib Malate | SIM-0702; SIM-1005; SIM-010603 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, Jilin Boda Pharmaceutical Co Ltd, Nanjing Yoko Biomedical Co Ltd | Neoplasms | Details |
| Nintedanib Esylate Inhalation Powder(Cspc) | Phase 1 Clinical | Cspc-Nbp Pharmaceutical Co Ltd | Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis | Details | |
| JSKN-027 | JSKN027; JSKN-027 | Phase 1 Clinical | Alphamab Oncology | Neoplasms; Solid tumours | Details |
| DPH-001 | DPH-001; DPH001 | Phase 1 Clinical | Disruptive Pharma AB | Details | |
| QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Solid tumours; Stomach Neoplasms | Details |
| Ramucirumab biosimilar (Klus Pharma) | A168; A-168 | Phase 1 Clinical | Klus Pharma Inc | Details | |
| MNKD-201 | MNKD-201; MKND-201 | Phase 1 Clinical | MannKind Corp | Idiopathic Pulmonary Fibrosis | Details |
| ETN-101 | ETN101; ETN-101; MBP-11901 | Phase 1 Clinical | Etnova Therapeutics Corp | Carcinoma, Hepatocellular; Liver Neoplasms | Details |
| RP-904 | Phase 1 Clinical | Risen (Suzhou) Pharma Tech Co Ltd | Solid tumours | Details | |
| RA1115-B1 | RA1115-B1 | Phase 1 Clinical | Suzhou Raymon Pharmaceuticals Co Ltd | Diabetic macular oedema; Macular Degeneration; Wet Macular Degeneration | Details |
| PZ-1 | PZ-1 | Phase 1 Clinical | Chongqing University Of Arts And Sciences | Solid tumours | Details |
| ICP-033 | ICP-033 | Phase 1 Clinical | Beijing Innocare Pharma Tech Co Ltd | Solid tumours | Details |
| PAN-90806 | OSI-632; CP-632; CP-547632; PAN-90806 | Phase 1 Clinical | Osi Pharmaceutical, Pfizer Inc | Abdominal Neoplasms; Diabetic Retinopathy; Fallopian Tube Neoplasms; Lung Neoplasms; Macular Degeneration; Ovarian Neoplasms; Peritoneal Neoplasms; Wet Macular Degeneration | Details |
| LMV-12(HE003) | LMV-12(HE003) | Phase 1 Clinical | Nanchang Hongyi Technology Co Ltd | Solid tumours | Details |
| Metatinib Trometamol | BMS-817378; SIM-817378 | Phase 1 Clinical | Bristol-Myers Squibb Company | Colorectal Neoplasms; Liver Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) | NP-01 | Phase 1 Clinical | Nanjing Nadingfei Pharmaceutical Technology Co Ltd, Shijiazhuang No 4 Pharmaceutical Co Ltd | Liver Neoplasms; Lung Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| FNX-006 | FNX-006 | Phase 1 Clinical | Chengdu Fannuoxi Biomedical Technology Co Ltd, Sichuan University | Melanoma; Triple Negative Breast Neoplasms | Details |
| Sorafenib tosylate (Bio-Synectics) | BS-104 | Clinical | Bio-Synectics Inc | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Anlotinib Dihydrochloride | AL-3818 | Approved | Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 福可维 | Mainland China | Carcinoma, Non-Small-Cell Lung | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2018-05-08 | Bile Duct Diseases; Bone Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Craniopharyngioma; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Gastroesophageal Junction Neoplasms; Gastrointestinal Stromal Tumors; Glioma; Head and Neck Neoplasms; Hepatic Insufficiency; Leiomyosarcoma; Liver Dysfunction; Lung Diseases, Interstitial; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Medullary thyroid cancer (MTC); Melanoma; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms; Neuroendocrine Tumors; Osteoma; Ovarian Neoplasms; Peritoneal Neoplasms; Sarcoma; Sarcoma, Alveolar Soft Part; Sarcoma, Synovial; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Thoracic Neoplasms; Thyroid Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms | Details |
| Lenvatinib Mesilate | E-7080; MK-7902; ER-203492-00 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Follicular; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Glioma; Hepatic Insufficiency; Liver Diseases; Liver Neoplasms; Lymphoma; Melanoma; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Osteosarcoma; Ovarian Neoplasms; Paraganglioma; Pheochromocytoma; Renal Insufficiency; Solid tumours; Stomach Neoplasms; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Uterine Cervical Neoplasms | Details |
| Axitinib | PF-01367866; AG-13736; AG-013736 | Approved | Pfizer Inc | 英立达, Inlyta | United States | Carcinoma, Renal Cell | Pf Prism Cv | 2012-01-27 | Adenocarcinoma; Adrenal Cortex Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Ductal; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Glioblastoma; Hepatic Insufficiency; Kidney Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Melanoma; Mesothelioma; Myelodysplastic Syndromes; Nasopharyngeal Neoplasms; Neoplasms; Neuroendocrine Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Paraganglioma; Pheochromocytoma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Uveal melanoma | Details |
| Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Adenocarcinoma; Adenoma; Bile Duct Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastrinoma; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Glucagonoma; Hemangiosarcoma; Insulinoma; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Melanoma; Meningioma; Neoplasm Metastasis; Neoplasms; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Rectal Neoplasms; Sarcoma; Sarcoma, Ewing; Solid tumours; Somatostatinoma; Stomach Neoplasms; Thymoma; Thyroid Neoplasms | Details |
| Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim International Gmbh | 2014-10-15 | Adenocarcinoma, Clear Cell; Appendiceal Neoplasms; Asbestosis; Astrocytoma; Breast Neoplasms; Carcinoid Tumor; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Endometrial Stromal Tumors; Esophageal Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Glioblastoma; Gliosarcoma; Hepatic Insufficiency; Idiopathic Pulmonary Fibrosis; Leukemia, Myeloid, Acute; Lung Diseases, Interstitial; Mesothelioma; Multiple Myeloma; Neoplasms; Oligodendroglioma; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Pulmonary Fibrosis; Radiation Pneumonitis; Rejection of lung transplantation; Sarcoma; Scleroderma, Systemic; Silicosis; Small Cell Lung Carcinoma; Solid tumours; systemic sclerosis-associated interstitial lung disease; Telangiectasia, Hereditary Hemorrhagic; Uterine Neoplasms | Details |
| Vorolanib | CM-082; X-82; EYP-1901; XV-615 | Approved | Tyrogenex Inc | 伏美纳, DURAVYU™ | Mainland China | Carcinoma, Renal Cell | Betta Pharmaceuticals Co Ltd | 2023-06-07 | Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Choroidal Neovascularization; Diabetic macular oedema; Diabetic Retinopathy; Eye Diseases; Gastroesophageal Junction Neoplasms; Kidney Neoplasms; Leukemia, Myeloid, Acute; Macular Degeneration; Melanoma; Neoplasms; Pancreatic Neoplasms; Retinal Degeneration; Retinal Diseases; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Wet Macular Degeneration | Details |
| Tivozanib | KRN-951; KHK-4951; KHK4951; UNII-172030934T; ASP-4130; Kil-8951; AV-951 | Approved | Kyowa Hakko Kirin Co Ltd | Fotivda, FOTIVDA | EU | Carcinoma, Renal Cell | Recordati Netherlands BV | 2017-08-24 | Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Fallopian Tube Neoplasms; Gastrointestinal Neoplasms; Hepatic Insufficiency; Metastatic breast cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Sarcoma; Solid tumours; Triple Negative Breast Neoplasms; Wet Macular Degeneration | Details |
| Apatinib Mesylate | YN-968D1 | Approved | Advenchen Laboratories Llc | 艾坦, Aitan | Mainland China | Stomach Neoplasms | Jiangsu shengdi Medicine Co Ltd | 2014-10-17 | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Esophageal Neoplasms; Esthesioneuroblastoma, Olfactory; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Melanoma; Metastatic breast cancer; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Ripretinib | DCC-2618 | Approved | Deciphera Pharmaceuticals | Qinlock, 擎乐 | United States | Gastrointestinal Stromal Tumors | Deciphera Pharmaceuticals Llc | 2020-05-15 | Gastrointestinal Stromal Tumors; Mastocytosis, Systemic; Neoplasms | Details |
| Ramucirumab | IMC-1121; IMC-1C11; LY-3009806; IMC-1121-B; BLA-125477 | Approved | Dyax Pharma | Cyramza | United States | Gastrointestinal Stromal Tumors | Eli Lilly And Company | 2014-04-21 | Adenocarcinoma; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoid Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Stromal Tumors; Melanoma; Metastatic breast cancer; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Solid tumours; Stomach Neoplasms; Ureteral Neoplasms; Urethral Neoplasms; Urologic Neoplasms | Details |
| Sunitinib Malate | PNU-290940AD; PHA-290940AD; SCAI-003; SU-010398; SU-11248; GB-102; PHA-290940; PNU-290940; SU-011248-L-malate salt | Approved | Pfizer Inc | Sutent, 索坦 | United States | Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell | Cppi Cv | 2006-01-26 | Abdominal Neoplasms; Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Islet Cell; Adrenocortical Carcinoma; AIDS-Related Complex; Amyloidosis; Angioimmunoblastic T-cell Lymphoma; Astrocytoma; Barrett Esophagus; Brain metastases; Brain Neoplasms; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Carcinoma, Acinar Cell; Carcinoma, Adenoid Cystic; Carcinoma, Adenosquamous; Carcinoma, Embryonal; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Choriocarcinoma; Chronic eosinophilic leukemia (CEL); Cognition Disorders; Colorectal Neoplasms; Diabetic macular oedema; Endodermal Sinus Tumor; Endometrial Neoplasms; Ependymoma; Esophageal Neoplasms; Fallopian Tube Neoplasms; Fibromatosis, Aggressive; Fibrosarcoma; Gastrointestinal Stromal Tumors; Germinoma; Glioblastoma; Glioma; Gliosarcoma; Head and Neck Neoplasms; Hemangi | Details |
| Pazopanib Hydrochloride | GSK-786034; GW-786034B; SB-786034; GW-786034 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | 维全特, Armala, Votrient, Patorma | United States | Carcinoma, Renal Cell; Sarcoma | Novartis Pharma Ag | 2009-10-19 | Adenocarcinoma, Follicular; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Embryonal; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Chondrosarcoma; Chondrosarcoma, Extraskeletal Myxoid; Choriocarcinoma; Colorectal Neoplasms; Dermatofibrosarcoma; Endodermal Sinus Tumor; Epistaxis; Fallopian Tube Neoplasms; Fibromatosis, Aggressive; Gastrinoma; Gastroenteropancreatic neuroendocrine tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genital Neoplasms, Female; Germinoma; Glioblastoma; Glioma; Gliosarcoma; Glucagonoma; Hemangiosarcoma; Herpes Genitalis; Herpes Simplex; HIV Infections; Hormone-Resistant Prostate Neoplasms; Insulinoma; Leiomyosarcoma; Leukemia, Myeloid, Acute; Liposarcoma; Lung Neoplasms; Lymphoma; Macular Degeneration; Medullary thyroid cancer (MTC); Melanoma; Mesothelioma; Multiple Endocrine Neoplasia T | Details |
| Cabozantinib S-malate | XL-184; BMS-907351; RO7047650; RO-7047650 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Thyroid Neoplasms; Carcinoma, Neuroendocrine | Exelixis Inc | 2012-11-29 | Adenocarcinoma, Clear Cell; Adenocarcinoma, Follicular; Adenoma, Islet Cell; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Astrocytoma; Bile Duct Neoplasms; Bone metastases; Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Glioblastoma; Glioma; Gliosarcoma; Hepatic Insufficiency; Hepatoblastoma; HIV Infections; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Lymphoma; Medullary thyroid cancer (MTC); Melanoma; Meningioma; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroendocrin | Details |
| Fruquintinib | HMPL-013; TAK-113 | Approved | FRUZAQLA, Aiyoute, Elunate, 爱优特 | Mainland China | Colorectal Neoplasms | Hutchison Medipharma Ltd | 2018-09-04 | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Hepatic Insufficiency; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Renal Insufficiency; Sarcoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details | |
| Sorafenib Tosylate | NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 | Approved | Onyx Pharmaceuticals Inc | Nexavar, 多吉美 | United States | Carcinoma, Renal Cell | Bayer Healthcare Pharmaceuticals Inc | 2005-12-01 | Abdominal Neoplasms; Adenocarcinoma; Angioimmunoblastic T-cell Lymphoma; Astrocytoma; Bile Duct Neoplasms; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Burkitt Lymphoma; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Cholangiocarcinoma; Colonic Neoplasms; Esophageal Neoplasms; Facial Neoplasms; Fallopian Tube Neoplasms; Fibromatosis, Aggressive; Gallbladder Neoplasms; Gastrinoma; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Gliosarcoma; Glucagonoma; Head and Neck Neoplasms; Heart Arrest; Hemangiosarcoma; Hepatopulmonary Syndrome; Histiocytoma, Malignant Fibrous; Hypertension, Portal; Hypopharyngeal Neoplasms; Insulinoma; Kidney Diseases; Kidney Neoplasms; Laryngeal Diseases; Laryngeal Neoplasms; Leiomyosarcoma; Leukemia, Basophilic, Acute; Leukemia, Eosin | Details |
| Vandetanib | AZD-6474; CH-331; ZD-6474 | Approved | Astrazeneca Plc | Zactima, Caprelsa | United States | Carcinoma, Neuroendocrine; Thyroid Neoplasms | Genzyme Corp | 2011-04-06 | Abdominal Neoplasms; Adenocarcinoma; Ampullary Carcinoma; Anus Neoplasms; Astrocytoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Diffuse Intrinsic Pontine Glioma; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Glioma; Gliosarcoma; Head and Neck Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Lung Neoplasms; Lymphoma; Lymphoproliferative Disorders; Medullary thyroid cancer (MTC); Mesothelioma; Metastatic breast cancer; Multiple Endocrine Neoplasia Type 2a; Multiple Endocrine Neoplasia Type 2b; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neuroblastoma; Oligodendroglioma; Ovarian Neoplasms; Pancreatic Neoplasms; Paraganglioma; Peritoneal Neoplasms; Pheochromocytoma; Pleural Effusion; Precancerous Co | Details |
| Famitinib Malate | SHR-1020 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾比特 | Mainland China | Uterine Cervical Neoplasms | Jiangsu Hengrui Medicine Co Ltd | 2025-05-27 | Adenocarcinoma; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Gastrointestinal Stromal Tumors; Genital Neoplasms, Female; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Metastatic breast cancer; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic neuroendocrine tumors (pNET); Small Cell Lung Carcinoma; Solid tumours; Thyroid Neoplasms; Triple Negative Breast Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms | Details |
| Midostaurin | PKC-412; PKC-412A; CGP-41231; CGP-41251 | Approved | Novartis Pharma Ag | Rydapt | United States | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Leukemia, Mast-Cell | Novartis Pharmaceuticals Corp | 2017-04-28 | Hematologic Neoplasms; Hepatic Insufficiency; Leukemia; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute; Mastocytosis; Mastocytosis, Systemic; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |